Back to Authors

Palace, Jacqueline

0000-0003-4779-6133

Mayo Clinic

Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.

Citations 26

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder

Neurology Neuroimmunology & Neuroinflammation | July 13, 2026 | Volume: 13 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000200609 | PMID 42441931

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Brain | February 2, 2026 | Volume: 149 | Issue: 6 | Pages: 1816-1818

10.1093/brain/awag035 | PMID 41630153

Ramdas et al. propose renaming ‘congenital myasthenic syndrome’ as ‘genetic myasthenic syndrome’. They argue that ‘congenital’ misleadingly implies neonatal onset, which may contribute to delayed diagnosis and management, and that revised nomenclature could improve patient outcomes.
Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Neurology | August 29, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000213903 | PMID 40882166

Effectiveness and Outcome Predictors of Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (S38.004)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210879

Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S38.007)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208711

Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s13.003

Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder and Concomitant Autoimmune Disease (4118)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.4118

Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1780

Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1765

Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1494